Market Access
The Trump administration leveraged tariffs to convince the UK National Health Service to increase prices for new medicines by 25%.
Biological E joins the ranks of Pfizer, GSK and Serum with WHO prequalification for its pneumococcal vaccine. As WHO's purchase data for Serum’s PSV10 indicate significant opportunity, Scrip spoke to Biological E on supply readiness and its application for exemption from price control in India
Under the Inflation Reduction Act, CMS negotiated lower Medicare Part D prices for 15 drugs with 2027 costs 38%-85% lower than 2024 list prices, but analyses of net prices paid last year show smaller discounts.
The second cycle of IRA price negotiations could result in price cuts as high as 85% to the 2024 list prices, but the mean discount across the 15 negotiated drugs appears similar to the previous round.
Madrigal, Wave Therapeutics and Kailera are in the next wave of cardiometabolic therapy companies, and at Jefferies talked about how US and China-derived innovation can help reach more patients in the US and the rest of the world.
Ohtuvayre is off to a great start in the US but Verona's new owner MSD has pulled the file from the EMA for the closely-watched chronic obstructive pulmonary disease drug.
Zydus looks to fill up its coffers ahead of the next round of acquisitions, likely in the specialty drugs space, while US FDA approvals for generics to Lynparza and Vumerity and its first approvals in China and Canada point to a healthy pipeline
With Novo Nordisk’s Wegovy joining Madrigal’s Rezdiffra as an FDA-approved MASH treatment, doctors now can choose between direct liver benefits or pursuing weight loss.
Wegovy and Zepbound will cost around $250 per month under Medicare and Medicaid, and the drugs will cost around $350 per month through TrumpRx.
Another strong quarter keeps AstraZeneca on track to meet its $80bn sales ambition, and its CEO maintains the recent Trump deal provides pricing reassurance, despite a lack of details so far.
Senior McKinsey executives discuss how biopharma can ace its US launch strategy and first-time launchers can stack the odds in their favor amid complex market dynamics including the MFN pricing push.
Experts from UCB, Alnylam, Lantheus and Medtronic deliberated at a recent summit best uses of agentic AI in the MLR review process, its human replaceability quotient and ways to balance creativity with compliance, a significant discussion amid DTC advertising and US FDA scrutiny.
The GLP-1 drugs Wegovy and Zepbound are cost effective at current prices, but affordability for the US healthcare system is an issue, according to ICER.
Experts at a recent summit discussed the complexities and impact of US MFN pricing from a payer perspective and emphasized the importance of a centralized purchaser of drugs to effectively negotiate prices. The potential rise of 'confidential discounts' in Germany was another key talking point.
Dupixent revenues were a record €4.16bn but the “negative buzz around vaccines” is hurting flu sales, according to chief financial officer François Roger.
Drug makers are reevaluating commercial opportunities outside the US in a post-MFN environment, according to experts at the BioFuture conference
Big pharma revenue exposure to Medicare and Medicaid varies; mounting US drug pricing pressure under the Trump Administration puts a spotlight on portfolio mix.
The drugmaker said it would make the PCSK9 inhibitor available to patients directly, just days after announcing positive data in patients without histories of strokes or heart attacks.
Leaders from Eli Lilly, Novo Nordisk, Biocon, Dr Reddy’s and Levim discuss the huge India market potential for GLP-1s. Executives from the Indian firms also outlined efforts to build supply chain stability and cost-efficiency for products like semaglutide.
The company’s agreement with the Trump Administration, which likely is a template for MFN deals with other companies, also includes a $70bn commitment to ‘reshoring’ development and manufacturing in the US.